Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Antisoma's TheraFab enters phase I lung cancer trial

Jan. 29, 2001

Genentech describes new series of DR4 modulators for cancer and immune-related diseases

Jan. 22, 2001

Maxim's NDA for histamine hydrochloride deemed unapprovable by FDA

Jan. 22, 2001

Ligand's Ontak enters phase II for CLL

Jan. 19, 2001

Viventia Biotech's melanoma vaccine is safe and immunogenic

Jan. 16, 2001

Peregrine reports promising interim results from Cotara brain cancer trial

Jan. 15, 2001

SciClone commences phase II study of Zadaxin as treatment for hepatocellular carcinoma

Jan. 12, 2001

Dendreon to commence clinical trials of APC-8024 in cancer patients

Jan. 11, 2001

Lorus Therapeutics' Virulizin shows better antitumor activity than Taxol in preclinical studies

Jan. 10, 2001

Phase II head and neck cancer trial of Multikine cleared in Mexico

Jan. 8, 2001

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...